Anxiety due to COVID-19 more prevalent in MG patients vs. public
Anxiety related to COVID-19 is more prevalent among people with myasthenia gravis (MG) than among the general population, a…
Articles by Andrea Lobo
Vyvgart may be safe, effective in treatment-resistant MG: Review
People with refractory myasthenia gravis (MG) who fail to respond to several treatments may be effectively treated with…
MG risk and immune system have a complex two-way connection
Certain inflammatory molecules known as cytokines may play a role in a person’s risk of developing myasthenia gravis (MG), according…
Thymectomy surgery may cause long-term immune changes in MG
Surgery to remove the thymus gland led to a long-term reduction in levels of immune T-cells and to temporary changes…
Overweight MG patients at greater risk of disease worsening: Study
A higher body mass index (BMI), a measure of body fat based on height and weight, is associated with an…
FDA clears Phase 2 trial testing C5 inhibitor IM-101 in MG patients
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 2 clinical trial testing IM-101, ImmunAbs’…
1st patient enrolled in Phase 3 trial of MG cell therapy Descartes-08
The first patient has joined a Phase 3 clinical trial assessing the safety and efficacy of Descartes-08, an investigational…
Generalized MG severity tied to misdiagnosis, certain symptoms
People with generalized myasthenia gravis (gMG) who were misdiagnosed at least once and who have certain disease symptoms are…
Rituximab treatment effective for 4-year-old’s MuSK-MG: Report
Rituximab may be safe and effective in treating young children with myasthenia gravis (MG) driven by antibodies that…
Telitacicept found to reduce gMG severity in Phase 3 trial in China
Treatment with Remegen’s telitacicept over nearly six months safely reduced disease severity in adults with generalized myasthenia gravis…